Gathering the record
Relay is organizing the evidence and source boundaries.
Copper(II)-binding tripeptide complex
GHK-Cu is a copper-binding tripeptide studied mostly in topical wound and skin settings. Human findings are mixed and formulation-specific. A new topical Phase 2 wound trial is recruiting, while standalone injectable benefits and safety remain unestablished.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
GHK-Cu is a small, naturally occurring peptide that binds copper. Researchers have examined finished GHK-Cu formulations mainly on skin and wounds, where copper-peptide biology may influence tissue repair.
Interest comes from its role in extracellular-matrix signaling and from early topical studies in wound care and cosmetic settings. The practical question is whether those laboratory effects become reliable, visible outcomes in people.
Human findings are mixed and formulation-specific. One older diabetic plantar-ulcer analysis reported improved closure, while a venous-stasis-ulcer trial found no advantage over vehicle. Small cosmetic studies have not produced a clear, consistent effect.
Modern replication, long-term topical outcomes, and the benefit and safety of standalone injectable GHK-Cu remain unknown. Results from a finished topical product cannot be transferred to injections, multi-ingredient products, or materials with unverified identity.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
Published human research tested a finished topical copper-tripeptide cream in people receiving care for venous stasis ulcers, with vehicle and active-comparator groups.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Several controlled topical studies, a recruiting split-wound trial, mixed-formulation reports, and laboratory mechanism work are available.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Some wound findings are encouraging, others are negative or mixed, and none establishes systemic injection benefits.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The older trial examined one cream formulation in one wound condition and found no advantage over vehicle for ulcer-size reduction. It does not establish cosmetic, injectable, systemic, or generalized recovery effects. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Randomized topical wound studies provide the strongest direct evidence, but results conflict by condition and formulation: a diabetic plantar-ulcer analysis was positive, while a venous-stasis-ulcer comparison was negative.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Standalone injectable pharmacokinetics, efficacy, repeated-exposure safety, immunogenicity, long-term topical outcomes, and whether older formulation-specific wound findings replicate in modern trials.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
FDA's substance record calls it prezatide copper and maps names including copper tripeptide-1, GHK copper, and GHK complex with copper.
A diabetic plantar-ulcer study reported improved closure with immediate Iamin Gel treatment, while a venous-stasis-ulcer study found no benefit for copper-complex cream versus vehicle.
Objective comparisons did not show significant group differences in wrinkles or overall skin quality, and erythema was not significantly reduced, although a patient questionnaire favored perceived skin quality.
It was an uncontrolled study of a six-component intradermal growth-factor formulation, so the contribution of copper tripeptide-1 cannot be separated.
The human evidence located is topical or involves an intradermal multi-ingredient hair formulation. FDA reports limited human safety data for compounded injectable GHK-Cu.
FDA cites potential aggregation and peptide-related impurities and says human data are limited for safety assessment.
FDA lists GHK-Cu except injectable routes in Category 1 and plans PCAC consultation before the end of February 2027.
The split-wound study plans to enroll 60 healthy adults and compare topical GHK-Cu gel with vehicle.
Cultured fibroblasts changed matrix synthesis after GHK-Cu exposure, but cell-culture endpoints do not directly measure patient outcomes.
The study used a multi-step procedure, red light, and a proprietary booster containing several ingredients; no results were posted by the cutoff.
Mechanisms
GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine, also indexed by FDA as prezatide copper. Laboratory studies report changes in fibroblast collagen and sulfated-glycosaminoglycan synthesis. Controlled human research is primarily topical: one diabetic plantar-ulcer program reported a positive immediate-treatment subgroup, a venous-stasis-ulcer trial was negative versus vehicle, and a small post-laser study found no clear objective recovery advantage. These findings do not establish systemic or subcutaneous use.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Controlled comparison of copper-tripeptide skin-care products after circumoral CO2 laser resurfacing
13 people undergoing CO2 laser resurfacing
Objective group comparisons did not show significant differences in wrinkles or overall skin quality, and the copper regimen did not significantly reduce post-treatment erythema. A patient questionnaire favored perceived overall skin quality.
Study administration: Topical copper-tripeptide skin-care regimen or comparator regimen after resurfacing
Limitations: Very small study with subjective and objective findings that did not fully agree. It tested a finished topical regimen after a procedure, not standalone injectable or systemic GHK-Cu.
Multicenter randomized evaluator-blinded vehicle-controlled study with immediate and delayed-treatment arms
People with diabetic neuropathic ulcers; reported benefit was concentrated in plantar-ulcer analyses
Immediate topical treatment produced greater median closure in the plantar-ulcer analysis than vehicle (98.5% versus 60.8%). Delayed-treatment comparisons did not show the same benefit.
Study administration: Topical Iamin Gel or vehicle after standardized debridement and wound care
Limitations: The publication is old and formulation-specific. Subgroup exclusions and the distinction between immediate and delayed treatment complicate interpretation. The result does not establish injectable, cosmetic, or generalized healing effects.
Prospective randomized evaluator-blinded comparison of topical creams
People with venous stasis ulcers
Silver sulfadiazine reduced ulcer size versus vehicle. The copper-complex cream did not differ from vehicle on ulcer-size reduction.
Study administration: 0.4% tripeptide copper complex cream, 1% silver sulfadiazine cream, or vehicle cream
Limitations: This older trial evaluated one topical formulation in venous stasis ulcers. It does not address injectable use, cosmetic outcomes, or systemic recovery.
Prospective single-arm study without a control group
1,000 people with hair loss
The uncontrolled study reported improved hair measures and tolerability for the multi-component formulation.
Study administration: Intradermal scalp injections of a formulation containing VEGF, bFGF, IGF, KGF, thymosin beta-4, and copper tripeptide-1
Limitations: No control group and six active components. The study cannot isolate any effect of copper tripeptide-1 and does not establish efficacy or safety of standalone injectable GHK-Cu.
Radiolabeled substrate study in normal human fibroblast cultures
Cultured normal human fibroblasts
GHK-Cu increased some sulfated glycosaminoglycans in culture but did not increase hyaluronic-acid synthesis.
Study administration: GHK-Cu across tested concentrations
Limitations: Laboratory matrix synthesis is not a demonstrated cosmetic, wound-healing, or systemic clinical outcome.
Human fibroblast culture experiment
Cultured human fibroblasts
GHK-Cu increased collagen synthesis in cultured fibroblasts at low tested concentrations.
Study administration: GHK-Cu across tested concentrations
Limitations: A cell-culture response is mechanistic evidence. It does not establish a visible skin outcome, wound closure, systemic anti-aging effect, dose, or safety in people.
Randomized double-blind vehicle-controlled split-wound study
Healthy adults with paired standardized punch-biopsy wounds
Recruiting as of July 25, 2026. No results were posted.
Study administration: Topical GHK-Cu gel versus matching vehicle gel, with each participant serving as their own control
Limitations: A registration describes what researchers plan to test; it does not demonstrate benefit. The study is topical and cannot answer injectable or systemic questions.
Completed open-label single-arm study of three multi-step Hydrafacial treatments
Healthy adults across Fitzpatrick skin types
The registry marks the study completed, but no results were posted on ClinicalTrials.gov by the review cutoff.
Study administration: Hydrafacial procedure, red-light treatment, and a proprietary multi-ingredient booster containing Cu-GHK among numerous components
Limitations: Open-label, no standalone GHK-Cu arm, and multiple procedural and ingredient components. Even future results could not isolate a GHK-Cu effect without a suitable comparator.
Safety snapshot
Injectable GHK-Cu raises unresolved immunogenicity and product-quality concerns.
No direct evidenceFDA's concern identifies uncertainty and plausible risk; it is not a quantified incidence estimate for every formulation.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Injectable GHK-Cu raises unresolved immunogenicity and product-quality concerns.
No direct evidenceFDA's concern identifies uncertainty and plausible risk; it is not a quantified incidence estimate for every formulation.
Open sourceThe current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-31
2026-05-14
2026-02-27 · NCT07437586
2023-07-07 · NCT05932732
2018-02-26 · PMID 29482481 · DOI 10.1080/14764172.2018.1439965
2006-07-01 · PMID 16847171 · DOI 10.1001/archfaci.8.4.252
1994-10-01 · PMID 17147644 · DOI 10.1046/j.1524-475X.1994.20406.x
1992-09-01 · PMID 1495150 · DOI 10.1067/mva.1992.37086
1992-09-01 · PMID 1522753 · DOI 10.1016/0024-3205(92)90504-I
1988-08-29 · PMID 3169264 · DOI 10.1016/0014-5793(88)80509-X